![]()
Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green).
PDB:
5CSZ. | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Beta-amyloid (Aβ40/42) |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6496H10072N1740O2024S42 |
Molar mass | 146276.71 g·mol−1 |
![]() ![]() |
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals. [1] [2]
Gantenerumab binds to and clears aggregated beta amyloid fibers. [3]
A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy. [4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease [5] but after five years of treatment, the drug did little to slow cognitive decline in patients. [6]
![]()
Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green).
PDB:
5CSZ. | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Beta-amyloid (Aβ40/42) |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6496H10072N1740O2024S42 |
Molar mass | 146276.71 g·mol−1 |
![]() ![]() |
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals. [1] [2]
Gantenerumab binds to and clears aggregated beta amyloid fibers. [3]
A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy. [4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease [5] but after five years of treatment, the drug did little to slow cognitive decline in patients. [6]